Innate Pharma strengthens its balance sheet with a $75M Sobi payment and $30M equity raise, supporting a robust clinical pipeline that includes upcoming Phase 3 data for monalizumab and ongoing development of its IPH4.5 thousand ADC candidate.
Innate Pharma's H1 2026 update highlights the closed lacutamab partnership with a $75M upfront payment, an extended cash runway into Q1 2028, and an on-track monalizumab Phase 3 readout, supporting a positive outlook.
Sobi closed the licensing transaction for lacutamab, making a $75M upfront payment with milestone and royalty obligations, expanding its oncology pipeline but adding near-term costs.
Innate Pharma has secured its financial future through a $75 million upfront payment from Sobi following the closure of their lacutamab licensing deal. The company confirmed its cash runway now extends into Q1 2028, while maintaining momentum on key clinical programs including the monalizumab Phase 3 readout expected in late 2026.
The transaction has officially closed, triggering a $75 million upfront payment to Innate Pharma and initiating the TELLOMAK-3 Phase 3 study.
Initial Phase 1 dose escalation data is scheduled for presentation at the EORTC-NCI-AACR Symposium on November 18, 2026.